GlassScriptPhysician profile
Antonio W Herold
NPI 1588286520
$22,569.35
in general payments reported to CMS, 2019-2025
16 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $299 · 2022: $858 · 2023: $1,519 · 2024: $2,141 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $5,962 · Travel and Lodging: $504 · Education: $71.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,875.00 |
| Food and Beverage | $5,961.95 |
| Travel and Lodging | $504.14 |
| Education | $71.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17,026.72 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,105.62 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $727.33 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Supernus Pharmaceuticals, INC. | $532.18 | 2024-2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $456.68 | 2023-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $403.84 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $395.44 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $371.66 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $325.67 | 2024-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $254.92 | 2021-2025 | Trintellix |
| Lundbeck LLC | $238.25 | 2021-2025 | Rexulti |
| Corium, LLC | $190.39 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $184.28 | 2021-2025 | Ingrezza |
| Sage Therapeutics, LLC | $135.96 | 2024-2025 | Zurzuvae |
| E.R. Squibb & Sons, L.L.C. | $132.25 | 2024-2025 | Cobenfy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $88.16 | 2022-2023 | Zimhi, Lucemyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Herold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.